Theriva Biologics, Inc.
TOVX · XNYSCIK 894158fmd_18MNB39EXBWCV079HW8X41QYMTManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | – | – | – |
| Research and development | 29 | 19 | 12 | 11 | 5 | 8 | 12 | 14 | 12 | 9 |
| Total operating expenses | 39 | 26 | 18 | 16 | 10 | 14 | 22 | 21 | 26 | 24 |
| Operating income | (39) | (26) | (18) | (16) | (10) | (14) | (22) | (21) | (26) | (24) |
| Interest expense | – | – | – | – | – | – | – | – | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Other non-operating income (expense) | 11 | 11 | 4 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Income before taxes | – | – | – | – | – | (14) | (21) | (20) | (26) | (24) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | (1) | (2) | 0 | – |
| Net income from continuing operations | – | – | – | – | – | (14) | (20) | (18) | (26) | – |
| Net income | (27) | (15) | (13) | (15) | (10) | (14) | (20) | (18) | (26) | (24) |
| Net income to common shareholders | (27) | (22) | (25) | (16) | (13) | (23) | (20) | (18) | (26) | (25) |